By Fineline Cube 
Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange for an initial public offering (IPO), marking a significant milestone for the Chinese surgical robotics developer founded in 2019.
Company Profile & Business Focus
| Item | Detail |
|---|---|
| Founded | 2019 |
| Headquarters | Shanghai, China |
| Core Business | Research, development, production, and commercialization of percutaneous puncture surgical robots |
| Listing Venue | Hong Kong Stock Exchange (pending approval) |
| Funding Objective | Accelerate international expansion, enhance R&D capabilities, and scale manufacturing |
Commercial Product – RC120 Platform
- Product: RC120 puncture surgical robot
- Regulatory Status: Approved as Category III medical device in China (2024)
- Commercial Availability: Currently marketed in select regions
- Significance: One of few domestically developed surgical robotics platforms to achieve full regulatory clearance in China’s competitive medtech landscape
Pipeline Portfolio – Expanding Clinical Applications
Simpletouch maintains an ambitious development pipeline targeting diverse surgical specialties:
| Product | Indication/Application | Development Stage |
|---|---|---|
| RC100 puncture surgical navigation and positioning system | General puncture procedures | Late-stage development |
| Spinal surgical navigation and positioning system | Spinal interventions | Pre-clinical/early clinical |
| Neurosurgical navigation and positioning system | Brain and neurological procedures | Pre-clinical/early clinical |
| CT-integrated puncture surgical navigation and positioning system | Image-guided interventions | Concept/prototype |
| Proprietary consumables | Used in conjunction with robotic platforms | Commercial/complementary |
Market Context & Strategic Outlook
- Global Surgical Robotics Market: Valued at $7.5 billion in 2025, projected to grow at >17% CAGR through 2030
- Competitive Landscape: Dominated by international players (Intuitive Surgical, Medtronic), with domestic Chinese companies rapidly gaining ground
- Investment Thesis: Capital from IPO expected to fund:
- International regulatory submissions (Europe, Southeast Asia)
- Enhanced R&D for next-generation platforms
- Manufacturing scale-up to meet anticipated demand
- Strategic partnerships with healthcare providers and imaging equipment manufacturers
Forward-Looking Statements
This brief contains forward-looking statements regarding Simpletouch Robot’s IPO timeline, product development, and market expectations. Actual results may differ due to risks including regulatory approvals, market adoption, competitive dynamics, and capital market conditions.-Fineline Info & Tech